Sign in Subscribe
Diseases

Repurposing Drugs to Tackle Alzheimer's and Parkinson's: A New Collaboration Aims to Accelerate Treatment Discovery

Strategic Insights

— 2 min read

Scientists from the fields of Alzheimer's and Parkinson's disease research are joining forces to explore the possibility of repurposing existing drugs to treat both conditions. This innovative approach seeks to leverage the knowledge and experience gained from the International Linked Clinical Trials (iLCT) project, which has already been "hugely successful" in identifying potential treatments for Parkinson's disease.

Key Takeaways:

  • The collaboration aims to identify current drugs that can target the common biological processes behind both Alzheimer's and Parkinson's diseases, such as inflammation, mitochondrial dysfunction, and protein misfolding.
  • Experts estimate that repurposing drugs could reduce the time patients are left waiting for new treatments by up to 10 years.
  • Semaglutide, a weight loss jab, is currently being investigated in clinical trials to see if it can help patients with Alzheimer's or Parkinson's disease.
  • The iLCT project has already identified around 30% of disease-modifying therapies for Parkinson's disease through its process, and the new collaboration seeks to replicate this success for Alzheimer's.
  • Dr. Sheona Scales, director of research at Alzheimer's Research UK, notes that this approach "increases the shots on target" at tackling the diseases and that repurposed drugs have already been demonstrated to be safe for use in humans.
  • Helen Matthews, chief executive of Cure Parkinson's, emphasizes the efficiency of this approach, stating that sharing knowledge and digging through existing data can save years in the drug development pipeline.
  • The sharing of knowledge and digging through existing data could also be applied to other disease areas, such as multiple sclerosis (MS).
  • Dr. Lucy Devendra, head of research at Alzheimer's Society, highlights the potential of repurposing medicines to find new treatments for dementia-causing diseases faster.

Statistics:

  • 30% of disease-modifying therapies for Parkinson's disease identified by the iLCT project.
  • 5-10 years of time savings in the drug development pipeline by repurposing existing drugs.
  • Semaglutide is being investigated in clinical trials to see if it can help patients with Alzheimer's or Parkinson's disease.
  • 10 years reduction in waiting time for new treatments.

Sources:

  • Cure Parkinson's: https://x.com/AlzResearchUK/status/1929856926885539966/photo/2
  • "Weight loss jab Semaglutide showing promising results in Alzheimer's trial": https://www.alzheimers.org.uk/news-and-research/our-research/news_archive/winter-season-2022-research-update
  • Dr. Sheona Scales' quote: "Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process."
  • Dr. Lucy Devendra's quote: "Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker."

Read more